Reuters | Published: January 19, 2021 18:34:40 | Updated: January 20, 2021 08:56:16
Russia's consumer health watchdog Rospotrebnadzor on Tuesday said Russia's second vaccine against COVID-19 is 100 per cent effective based on the results of clinical trials, the TASS news agency reported.
Russia began mass trials of EpiVacCorona, which is being developed by Siberia's Vector Institute, in November.
Moscow has said its other approved COVID-19 vaccine, Sputnik V, is 92 per cent effective at protecting people from COVID-19 according to interim results.
Germany's Scholz says want to deepen relations with India, meets Modi
Yellen, G7 urge renewed aid for Ukraine as G20 finance chiefs gather
78m children don’t go to school at all: UN chief
S Korea, US to hold simulated drill on North use of nukes
Earthquake fans anti-Syrian sentiment in Turkey amid desperate conditions
Global Covid-19 cases near 678m
Turkey detains building contractors as quake deaths pass 33,000
Death toll in Turkey, Syria quake tops 28,000
Seven police officers killed in cocaine hotspot of central Peru
World must remember those displaced by quake in Turkey, Syria: UN
© 2024 - All Rights with The Financial Express
